BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation – design, synthesis and biological evaluation
Authors:
Open Access
- 18 July 2023
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 165, 115161
Abstract
No abstract availableKeywords
Funding Information
- Narodowe Centrum Nauki (UMO-2017/26/D/ST5/00919)
This publication has 70 references indexed in Scilit:
- HVEM signalling at mucosal barriers provides host defence against pathogenic bacteriaNature, 2012
- The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulationImmunological Reviews, 2011
- T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cellsJournal of Immunological Methods, 2010
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationJournal of Clinical Investigation, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Targeting lymphocyte activation through the lymphotoxin and LIGHT pathwaysImmunological Reviews, 2008
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJournal of Clinical Investigation, 2007
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- 1H, 13C and 15N chemical shift referencing in biomolecular NMRJournal of Biomolecular NMR, 1995